Dr. Miguel Santos
iMed - FFUL
Miguel Santos holds a BSc and a MSc degree in Biochemistry, Old Dominion University, VA, USA; a PhD in Molecular Biology, ITQB/UNL, PT; a Post-Doctorate in Genomics, UA, PT; and Post Grad degrees in Project Management Proficiency (PMP Intl.), UAL, PT; Mini-MBA in Global Biopharma Entrepreneurship, Rutgers University, NJ, USA; and a MBA from the Institute of Business Management, ISCTE/FE Univ. Porto. Miguel has managed and led several scientific projects both in academic and industry settings and coordinated the settlement of several services and brands in the Biotechnology market. Miguel’s latest permanent position was as COO at ECBio S.A., where he worked for 11 years in the development of Advanced Therapy Medicinal Products (ATMP) based on mesenchymal stem cells (MSC).
Miguel’s main activities as COO involved coordinating pre-clinical research projects in compliance with EMA regulations; intellectual property (IP) management; technology transfer mediation and new-business development. Miguel is currently an Invited PI at ITQB NOVA where he coordinates the StartUp Research Bio-Entrepreneurship Program. Besides, Miguel offers Bio-Pharma Consulting to Spin-Off and StartUp Biotech ventures. In terms of research, Miguel is an affiliated PI at the Animal Science Studies Centre (CECA/ICETA) and to the Medicines Institute (iMed – FFUL). Miguel’s present interest is to continue developing R&D on MSC-based AMTPs focused on veterinary use but with a One-Health perspective. Miguel has a considerable portfolio of scientific publications and patents in the areas of control of gene expression and stem cell therapy. Miguel has recently been appointed as an (external) Member to the Commission of Advanced Therapeutics’ Evaluation at INFARMED, PT; and he is member of the Executive Board of the Portuguese Stem Cell Society.